Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
14 March 2022 |
Main ID: |
EUCTR2015-002674-20-SE |
Date of registration:
|
02/10/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria
|
Scientific title:
|
A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria |
Date of first enrolment:
|
30/11/2015 |
Target sample size:
|
18 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002674-20 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: yes Open: yes Single blind: Double blind: Parallel group: Cross over: Other: If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Canada
|
Finland
|
France
|
Germany
|
Russian Federation
|
Spain
|
Sweden
|
Taiwan
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
European Clinical Trial Information
|
Address:
|
1-15 avenue Edouard Belin
92500
Rueil-Malmaison
France |
Telephone:
|
+33147100606 |
Email:
|
clinicaltrials.eu@alxn.com |
Affiliation:
|
ALEXION EUROPE SAS |
|
Name:
|
European Clinical Trial Information
|
Address:
|
1-15 avenue Edouard Belin
92500
Rueil-Malmaison
France |
Telephone:
|
+33147100606 |
Email:
|
clinicaltrials.eu@alxn.com |
Affiliation:
|
ALEXION EUROPE SAS |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Male or female patients = 18 years of age
2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry (red blood cells [RBCs] and/or granulocytes)
3. Mean lactate dehydrogenase (LDH) =3 × upper limit of normal, based on 2 measurements from separate blood samples collected at least 1 day apart during screening
4. Willing and able to give written informed consent and comply with the study visit schedule
5. Documented meningococcal vaccination not more than 3 years prior to dosing
6. Female patients who consider themselves postmenopausal must provide evidence at screening of menopause status, based on a combination of amenorrhea for at least 1 year and increased serum follicle-stimulating hormone level (> 30 IU/L) on at least 2 occasions (eg, in the absence of hormone replacement therapy, dietary phytoestrogens) or estradiol concentration < 10 pg/mL.
7. Female patients of childbearing potential must use highly effective contraception as defined below, starting at screening and continuing until at least 6 months after the last dose of ALXN1210.
8. Male patients with a female spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or partner must agree to use barrier contraception (male condom) during the Treatment Period and for at least 6 months after the last dose of ALXN1210. Barrier contraception is required even with documented medical assessment of surgical success of a vasectomy. Female spouses/partners of male patients who are of childbearing potential must use highly effective contraception or acceptable contraception, as defined below, starting at screening and continuing until at least 6 months after the last dose of ALXN1210. Male patients must not donate sperm during the
Screening and Treatment Periods and for at least 6 months after the last dose of ALXN1210.
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 3
Exclusion criteria: 1. Treatment with a complement inhibitor at any time
2. Platelet count < 30,000/mm3 (30 × 109 /L) at screening
3. Absolute neutrophil count < 500/µL (0.5 × 109 /L) at screening
4. History of bone marrow transplantation
5. History of Neisseria meningitidis infection; history of unexplained, recurrent infection; or infection requiring treatment with systemic antibiotics within the last 90 days prior to dosing on Day 1
6. Female patients who are planning to become pregnant, or are pregnant or breastfeeding
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) MedDRA version: 18.0
Level: LLT
Classification code 10055629
Term: Paroxysmal nocturnal hemoglobinuria
System Organ Class: 100000004857
|
Intervention(s)
|
Product Code: ALXN1210 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ALXN1210 Current Sponsor code: ALXN1210 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-
|
Primary Outcome(s)
|
Main Objective: To evaluate the efficacy, safety, and tolerability of multiple doses of ALXN1210 administered intravenously (IV) to complement inhibitor treatment-naïve patients with PNH
|
Primary end point(s): Change in LDH levels from baseline to Day 253
|
Timepoint(s) of evaluation of this end point: Day 1, 7, 15, 22, 29, 43, 57, 85, 113, 127, 141, 169, 197, 211, 225, 253
|
Secondary Objective: The secondary objectives of the trial are: - To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) effects of multiple doses of ALXN1210 administered IV to complement inhibitor treatment-naïve patients with PNH - To investigate the immunogenicity of ALXN1210 administered IV to complement inhibitor treatment-naïve patients with PNH
|
Secondary Outcome(s)
|
Secondary end point(s): Efficacy endpoints:
- Changes in hemolysis-related hematologic parameters
- Changes in clinical manifestations
Safety endpoints:
- Change from baseline in the need for blood transfusions
- Change from baseline in disease-associated biomarkers
- Change from baseline in quality of life
- Change from baseline in major adverse vascular events (MAVEs)
Immunogenicity: Measurement of antidrug antibodies (ADA)
Pharmacokinetic/Pharmacodynamic
Safety
|
Timepoint(s) of evaluation of this end point: Day 1, 7, 15, 22, 29, 43, 57, 85, 113, 127, 141, 169, 197, 211, 225, 253
|
Secondary ID(s)
|
2015-002674-20-DE
|
ALXN1210-PNH-201
|
Source(s) of Monetary Support
|
ALEXION PHARMACEUTICALS INC
|
Ethics review
|
Status: Approved
Approval date: 30/11/2015
Contact:
|
|